ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Thomas K. Varghese, Jr
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varghese, T. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varghese, T. K., Jr
Related Collections
Right arrow Lung - transplantation

Ann Thorac Surg 2006;82:478-479
© 2006 The Society of Thoracic Surgeons


Original Articles: General Thoracic

Invited commentary

Thomas K. Varghese, Jr, MD

Section of Thoracic Surgery, University of Michigan, 2120 Taubman Center, 1500 E Medical Center Dr, Ann Arbor, MI 48109

(Email: vargthom{at}umich.edu).

Ischemia–reperfusion lung injury resulting in pulmonary dysfunction is a major source of morbidity and mortality after cardiac surgery and lung transplantation. Transbronchial biopsies performed after lung transplantation demonstrate histologic features of diffuse alveolar damage in more than 30% of patients [1]. This is associated with severe graft dysfunction in about 20% of recipients [2], and is the most common cause of early mortality after lung transplantation [3–5]. Postoperative lung dysfunction after cardiopulmonary bypass is also in part associated with lung ischemia–reperfusion injury [6].

The events after ischemia–reperfusion, although closely related, cause lung injury by activation of different inflammatory pathways [6, 7]. The authors of the present report [8], used a well-established rodent model of lung ischemia–reperfusion injury [9] to analyze the role of interlukin-6 (IL-6). In hemorrhagic and endotoxin-induced shock models, both systemically and locally given IL-6 decreased neutrophil extravasation, inhibited inflammatory cytokines such as tumor necrosis factor-{alpha}, decreased tissue permeability, and improved animal survival [10–14].

Signal transducers and activators of transcription (STAT) factors are a family of cytoplasmic transcription factors that mediate intracellular signaling initiated at cytokine cell surface receptors and transmitted to the nucleus. Different STATs are activated by distinct groups of cytokines, with interferon-{gamma} activating STAT-1 and IL-6 classically described as activating STAT-3. In the present report, however, IL-6 was found to reduce STAT-3 activation. STAT-1 has been shown to induce apoptosis in cardiac myocytes, whilst STAT-3 is able to protect cardiac myocytes after ischemia–reperfusion [15]. A direct correlation between the degree of apoptosis and pulmonary dysfunction after ischemia–reperfusion remains controversial, however, with the deterioration in lung function correlating to the degree of necrosis and not apoptosis [16].

These are just some examples of the difficulties that have been encountered during the elucidation of molecular events of ischemia–reperfusion and attempting to correlate their clinical importance. The role of exogenous IL-6 in inhibiting NF{kappa}B has been studied in one other publication [15], and the present work describes the activation pattern of STAT-3 after lung ischemia–reperfusion injury.

The limitations of current therapies largely arise from our limited understanding of the molecular events that modulate the severity of damage that arises from ischemia–reperfusion injury. Understanding these underlying cellular and molecular signaling events is critical to the development of new therapeutic approaches.


    References
 Top
 References
 

  1. Gammie JS, Cheul LJ, Pham SM, et al. Cardiopulmonary bypass is associated with early allograft dysfunction but not death after double-lung transplantation J Thorac Cardiovasc Surg 1998;115:990-997.[Abstract/Free Full Text]
  2. Khan SU, Salloum J, O'Donovan PB, et al. Acute pulmonary edema after lung transplantationthe pulmonary reimplantation response. Chest 1999;116:187-194.[Medline]
  3. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantationtwenty-second official adult heart transplant report—2005. J Heart Lung Transplant 2005;24:945-955.[Medline]
  4. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantationtwenty-second official adult lung and heart-lung transplant report—2005. J Heart Lung Transplant 2005;24:956-967.[Medline]
  5. Boucek MM, Edwards LB, Keck BM, Trulock EP, Taylor DO, Hertz MI. Registry of the International Society for Heart and Lung Transplantationeighth official pediatric report—2005. J Heart Lung Transplant 2005;24:968-982.[Medline]
  6. Ng CSH, Wan S, Yim APC, Arifi AA. Pulmonary dysfunction after cardiac surgery Chest 2002;121:1269-1277.[Medline]
  7. de Perot M, Liu M, Waddell TK, Keshavjee S. Ischemia-reperfusion-induced lung injury Am J Respir Crit Care Med 2003;167:490-511.[Abstract/Free Full Text]
  8. Farivar AS, Merry HE, Fica-Delgado MJ, et al. Interleukin-6 regulation of direct lung ischemia reperfusion injury Ann Thorac Surg 2006;82:472-479.[Abstract/Free Full Text]
  9. Krishnadasan B, Naidu BV, Byrne K, Fraga C, Verrier ED, Mulligan MS. The role of proinflammatory cytokines in lung ischemia-reperfusion injury J Thorac Cardiovasc Surg 2003;125:261-272.[Abstract/Free Full Text]
  10. Rollwagen FM, Li YY, Pacheco ND, Dick EJ, Kang YH. Microvascular effects of oral interleukin-6 on ischemia/reperfusion in the murine small intestine Am J Pathol 2000;156:1177-1182.[Medline]
  11. Ulich TR, Yin S, Guo K, Yi ES, Remick D, del Castillo J. Intratracheal injection of endotoxin and cytokines. II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation Am J Pathol 1991;138:1097-1101.[Medline]
  12. Rollwagen FM, Li YY, Pacheco ND, Nielsen TB. Systemic bacteraemia following haemorrhagic shock in micealleviation with oral Interleukin 6. Cytokine 1996;8:121-129.[Medline]
  13. Barton BE, Shortall J, Jackson JV. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model Infect Immun 1996;64:714-718.[Abstract/Free Full Text]
  14. Meng ZH, Dyer K, Billiar TR, Tweardy DJ. Distinct effects of systemic infusion of G-CSF vs. IL-6 on lung and liver inflammation and injury in hemorrhagic shock Shock 2000;14:41-48.[Medline]
  15. Stephanou A. Role of STAT-1 and STAT-3 in ischaemia/reperfusion injury J Cell Mol Med 2004;8:519-525.[Medline]
  16. Fischer S, Maclean AA, Liu M, et al. Dynamic changes in apoptotic and necrotic cell death correlate with severity of ischemia-reperfusion injury in lung transplantation Am J Respir Crit Care Med 2000;162:1932-1939.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Thomas K. Varghese, Jr
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varghese, T. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varghese, T. K., Jr
Related Collections
Right arrow Lung - transplantation


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS